Barrow Receives DoD Grant to Repurpose Existing Drug for ALS

The United States Department of Defense (DoD) has awarded Barrow Neurological Institute an $840,000 grant to repurpose an existing class of drugs to target a specific molecular pathway that scientists have recently linked to ALS and other neurodegenerative diseases.

The two-year Therapeutic Idea Award—led by David Medina, PhD, an assistant professor in the Bowser Laboratory in the Department of Translational Neuroscience at Barrow—aims to increase our understanding of the role of m6A dysregulation in ALS and determine whether targeting this dysregulation with small-molecule drugs can reduce progression of the disease. 

“While recent ALS clinical trial success has occurred for specific genetic forms of ALS, the vast majority of patients who lack a genetic cause do not have effective treatment. Dr. Medina’s study may provide a new drug treatment for the majority of ALS patients, which is very exciting.”

-Robert Bowser, PhD, Chief Scientific Officer, Barrow Neurological Institute

ALS, short for amyotrophic lateral sclerosis and commonly referred to as Lou Gehrig’s disease, involves the deterioration and death of motor neurons. The loss of these nerve cells affects a person’s ability to move, speak, eat, and breathe.

While available medications can modestly slow ALS progression and other therapies can help alleviate symptoms and improve quality of life for patients, no treatments exist to halt or reverse the progression of the disease. The average survival time after diagnosis is about three to five years. This underscores the urgent need for the development of new, more effective treatments.

This is especially important for patients with the sporadic form of the disease, said Robert Bowser, PhD, who leads the laboratory where Dr. Medina works and serves as Chief Scientific Officer of Barrow. “While recent ALS clinical trial success has occurred for specific genetic forms of ALS, the vast majority of patients who lack a genetic cause do not have effective treatment,” Dr. Bowser said. “Dr. Medina’s study may provide a new drug treatment for the majority of ALS patients, which is very exciting.”

What Is m6A, and Why Does it Matter?

The human body can’t operate without proteins. These complex molecules play a crucial role in ensuring our cells, tissues, and organs function properly. To make proteins, our cells rely on instructions from our DNA, which arrive via messenger molecules called RNA. During the lifecycle of RNA, many modifications occur—the most common of which is known as m6A.

“Previously, m6A was studied in the context of cancers, but eventually people started looking at its role in neurodegeneration,” Dr. Medina explained. “Its dysregulation has been connected to ALS probably within the last five years or so.”

Researchers have implicated the m6A modification in various mechanisms of disease in general, such as the body’s response to oxidative stress (an imbalance of harmful free radicals and the antioxidants that neutralize them), inflammation of the nervous system, and disrupted communication between nerve cells. Studies have also shown reduced m6A modification levels in various diseases. These findings led Dr. Medina and his team to hypothesize that by increasing levels of m6A modification, they can decrease markers of ALS in various models of the disease.

Targeting m6A: A New Use for Known Drugs

One way to restore levels of m6A modification is by targeting a group of proteins called “erasers.” “The m6A pathway is dynamic,” Dr. Medina said. “It has groups of proteins that write the modification onto the RNA, and then there are proteins that read that modification. How they read it is how they regulate the fate of these RNAs. Then, finally, the eraser proteins actually remove the modification from RNA.”

David Medina, PhD
David Medina, PhD

One of the main erasers in the brain is known as the “fat- and obesity-associated protein” (FTO), and drugs that can inhibit FTOs already have approval from the U.S. Food and Drug Administration (FDA) for other uses.

One of these drugs is entacapone, which clinicians typically prescribe to help people with Parkinson’s disease manage their symptoms between doses of the gold-standard Parkinson’s drug, levodopa. While entacapone slows the breakdown of levodopa in the body, it has the secondary effect of suppressing FTOs and increasing m6A modification levels. “We see it as a good opportunity to quickly try this strategy in the clinic because entacapone has a good safety profile, and we know quite a bit about it,” Dr. Medina said. “But applying it in the context of m6A, that’s the novel part.”

Thanks to Barrow Neurological Foundation and the Arizona Alzheimer’s Consortium, Dr. Medina and his team gathered promising preliminary data showing that entacapone elevates m6A levels in mice. While he and his team will use entacapone as their lead drug candidate in this study, they also plan to investigate newer FTOs in tandem.

Artak Tovmasyan, PhD, an associate professor at Barrow who leads a laboratory focused on how pharmaceutical drugs affect the body, will lend his expertise as a co-investigator to try to identify the ideal FTO and dosage for targeting the m6A modification pathway in ALS.

Measuring Success: Developing Biomarkers

In order to determine how effective entacapone and other FTO inhibitors could be in treating ALS, the researchers will need measurable indicators of disease progression. Developing ALS biomarkers is already a core focus of the Bowser Laboratory.

Drs. Medina and Bowser will collaborate with co-investigator Kendall Van Keuren-Jensen, PhD, at the Translational Genomics Research Institute (TGen) to identify biomarkers in cerebrospinal fluid and plasma samples from human donors. Barrow already has these samples on hand through Dr. Bowser’s work with the Target ALS consortium.

Robert Bowser, PhD
Robert Bowser, PhD

Not only are biomarkers essential to disentangling m6A’s role in ALS and evaluating the effectiveness of therapies targeting this pathway, but they could also help researchers classify patients and thus pave the way for a personalized-medicine approach to ALS treatment.

“Is m6A dysregulated in every patient? Probably not,” Dr. Medina said. “But maybe if we learn something about the biomarkers, we can understand: Is this pathway associated with fast-progressing or slow-progressing patients? Is it associated with a genotype of a patient? We don’t know those things yet.”

That’s where co-principal investigator Ashley Boehringer, PhD, comes in. A research assistant professor at Arizona State University, Dr. Boehringer will use induced pluripotent stem cells (iPSCs)—nerve cells that have been reprogrammed from blood or skin cells—to probe how other disease-associated proteins affect the m6A pathway and identify who might actually respond to this therapeutic target.

“We have a goal of trying to get help to patients as quickly as possible,” Dr. Medina said. “I think that’s what made the m6A story so exciting. It’s a pathway that was being studied somewhere else, so there are drugs out there already that we can be using. We don’t have to develop them ourselves just yet. Can we improve them? Probably, but first let’s show whether they might work.”

Want stories like this delivered to your inbox? Sign up for our award-winning newsletter.